Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
for
Advanced Melanoma
Location: 17 recruiting locations
Sponsor: Immunocore Ltd
Sex: All
Age: 18+
Code: NCT05549297
Phase3, Recruiting
Active & Responsive
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
for
Melanoma, Unresectable Solid Tumors, Neoplasms,
Location: 2 recruiting locations
Sponsor: Yana Najjar
Sex: All
Age: 18+
Code: NCT04572451
Phase1, Recruiting
Active & Responsive
Evaluation of Hypoxia in Primary Melanoma
for
Melanoma
Location: 1 recruiting location
Sponsor: Yana Najjar
Sex: All
Age: 18+
Code: NCT06831071
Recruiting
Active & Responsive
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies